Isolation and identification of T cells
View Patent ↗The present invention relates to improved autologous T cell vaccines and improved methods for their production. The invention is also directed to methods for treating autoimmune diseases such as multiple sclerosis or rheumatoid arthritis using autologous T cell vaccines. The invention is further directed to the diagnosis of T cell associated diseases.
1. An autologous T-cell vaccine consisting of inactivated T cells that are reactive against SEQ ID NOS: 1-6.
2. An autologous T cell vaccine comprising inactivated T cells elicited from a patient sample comprising mononuclear cells by a combination of antigens consisting of SEQ ID NOS:1-6.
3. The T cell vaccine according to claim 1 , wherein the T cells are inactivated by irradiation.
4. The T cell vaccine according to claim 2 , wherein the T cells are inactivated by irradiation.
5. The T cell vaccine according to claim 2 , wherein the patient sample comprises peripheral blood T cells.
6. The T cell vaccine according to claim 2 wherein the patient sample comprises cerebrospinal fluid T cells.
7. A method of treating multiple sclerosis comprising administering to a patient in need thereof the autologous T cell vaccine according to claim 1 .
8. A method of treating multiple sclerosis comprising administering to a patient in need thereof the autologous T cell vaccine according to claim 2 .